

28 April 2026

Appointment of Chief Executive Officer

EVE Health Group Limited (ASX: EVE, EVE or the Company) is pleased to announce the appointment of Mr Ben Rohr as Chief Executive Officer, effective immediately.

Mr Rohr has been instrumental in the Company's recent operational and commercial progress and brings a strong track record in execution, operational leadership and capital management. His appointment reflects the Board's focus on accelerating the commercialisation of EVE's product portfolio and delivering disciplined growth across the business.

Mr Rohr has been serving as Chief Operating Officer and has played a central role in the execution of the Company's strategy, including leading the integration of the Nextract acquisition and advancing the Company's pharmaceutical and commercial development programs. He has also been closely involved in positioning the Company's core products, Dyspro® and Libbo®, for regulatory progression and commercial rollout.

Commenting on the appointment, Chairman Rod Hannington said: "Ben has demonstrated strong leadership and a clear ability to execute on the Company's strategy. His deep understanding of the business, combined with his commercial focus, positions him well to lead EVE through its next phase of growth."

As part of this transition, Mr Damian Wood is stepping down from the role of Chief Executive Officer.

The Company intends to retain Mr Wood in the role of Head of Regulatory and Medical Affairs, with responsibility for regulatory strategy, clinical development and medical affairs across the Company's product pipeline.

Mr Wood has been instrumental in advancing the Company's regulatory and clinical programs, and the Board looks forward to his continued contribution in this focused role.

The Board considers that this revised structure appropriately aligns the Company's executive leadership with its strategic priorities, combining strong commercial execution with dedicated regulatory and clinical expertise.

Further details regarding executive arrangements are enclosed in Appendix 1.

Authorised for release by the Board of Directors.

Company enquiries

+61 8 6465 5500

info@evehealthgroup.com.au

About EVE Health Group

EVE Health Group (ASX: EVE) is an Australian life sciences company focused on developing and commercialising innovative pharmaceutical solutions in high-growth therapeutic areas. The company's lead assets include Dyspro®, a fast-acting cannabinoid-based pastille targeting dysmenorrhoea and endometriosis, and Libbo®, an oral dissolving film for erectile dysfunction designed to deliver rapid onset and improved patient convenience. Both products leverage EVE's proprietary formulation and delivery technologies to enhance bioavailability and clinical outcomes, representing near-term commercial opportunities in large, underserved global markets.

EVE is building a vertically integrated health platform that combines proprietary pharmaceutical products with digital education, patient engagement and prescribing pathways. Through its dedicated information platforms, ReclaimMyCycle.com (women's health) and StiffIssue.com (men's health), the Company provides condition-focused education, reduces stigma and supports earlier engagement with appropriate care. These platforms integrate with telehealth and pharmacy fulfilment networks to enable responsible, scalable access to treatment within a regulated healthcare framework.

For further information, please visit www.evehealthgroup.com.au and follow us on LinkedIn.

Appendix 1

Title	Chief Executive Officer
Commencement Date	27 April 2026
Base Salary	\$220,000 per annum plus superannuation
Notice Period	3 months' notice by either party
Long Term Incentive	<p>Mr Rohr currently holds 2,900,000 unlisted options under the Company's Employee Incentive Plan, exercisable at \$0.06 per option with a 3-year term.</p> <p>Unlisted options were issued in December 2025 as part of Mr Rohr's existing employment agreement.</p>